Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 3 Trials for Denosumab (DB06643)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02051218Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 WeeksSupportive Care